Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-2173 + Tenofovir in Chronic Hepatitis B and D
NCT04847440Phase 2Terminated
- Sponsor
- Antios Therapeutics
- Start
- Mar 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ATI-2173 in Chronic Hepatitis B (CHB), hepatitis D (HDV), sponsored by Antios Therapeutics. Started Mar 2021; status: terminated.
02
Drugs
ATI-2173
03
Conditions
Chronic Hepatitis B (CHB)hepatitis D (HDV)
Beyond the preview
Go deeper on NCT04847440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04847440.